Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

NCT02014337 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Ovarian Epithelial Cancer Recurrent
Sarcoma
Non-small Cell Lung Cancer
Carcinoma, Transitional Cell
Prostate Cancer
Prostatic Neoplasms

Interventions

DRUG: Mifepristone and Eribulin in combination

Sponsor

Corcept Therapeutics